The data are encouraging on safety but response rates are comparable to SOC, not superior — the lack of PFS maturity and small sample sizes limit de-risking. Watch for further Duravelo-2 randomized data in 2H 2026, which will be the key catalyst.
Price Chart
Executive Summary
Bicycle Therapeutics announced initial Phase 2 Duravelo-2 data for zelenectide pevedotin in metastatic urothelial cancer, showing response rates comparable to standard of care with a potentially differentiated safety profile. The filing is a clinical data update with no financial figures, and the data are still early (median PFS not mature); further results expected in 2H 2026.
Key Facts
- Duravelo-2 (Cohort 1): at optimal dose, confirmed ORR of 58% (15/26) by BICR at 27-week cutoff; 62% (16/26) after later response
- Median duration of treatment was 6.3 months; 65% of patients remain on treatment at data cutoff
- Cohort 2 (monotherapy, prior therapy): confirmed ORR 30% (8/27); median duration of treatment 4.8 months
- Safety: peripheral neuropathy (33% Cohort 1), skin reactions (17%), no Grade 4/5 AEs; only one discontinuation at optimal dose
- Updated Duravelo-1 (Phase 1, cisplatin-ineligible): confirmed ORR 50% (11/22), median PFS 13.0 months
- Median PFS not mature in Duravelo-2; further randomized Phase 2 data expected in 2H 2026
- No financial data, guidance, or capital allocation decisions included in this filing
Financial Impact
No financial figures provided; clinical data update only
Risk Factors
- Response rates are comparable, not superior, to standard of care — no clear differentiation in efficacy
- Median PFS not yet mature; durability of responses unknown
- Small sample sizes (n=26 in Cohort 1) limit statistical reliability
- Further data expected in 2H 2026 creates extended catalyst timeline
- Pre-revenue clinical-stage biotech: high binary risk on future randomized readout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-065231 |
| Document: tm2615187d1_8k.htm | 0001104659-26-065231 |
| Document: 0001104659-26-065231-index-headers.html | 0001104659-26-065231 |
| Document: 0001104659-26-065231-index.html | 0001104659-26-065231 |
| Document: 0001104659-26-065231.txt | 0001104659-26-065231 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3/A | $3.73 | awaiting T+60 | — | $3.65 (−2.14%) |
Jul 30, 2026 12w ago | 8-K | $4.01 $3.55 | ▼ −11.47% | ▼ −13.94% | $3.65 (−8.98%) |
May 21, 2026 22w ago | 8-K | $4.55 $3.99 | ▼ −12.31% | ▼ −15.50% | $3.65 (−19.78%) |
Apr 20, 2026 27w ago | 8-K | $5.29 $4.22 | ▼ −20.23% | ▼ −27.00% | $3.65 (−31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers